Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 823 results for "eisai"

Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai Inc.
International Business Times

Eisai to launch antiepileptic drug, Fycompa tablets

Eisai Co., Ltd, a research-based human health care company, announced that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures ... PharmaBiz, 5 days ago
Eisai to launch Fycompa in Japan this month Pharma Letter, 6 days ago

18 images for eisai

American Banking News - Stock Ratings, 1 week ago
Mideast Time, 1 week ago
Pharmaceutical Technology, 2 weeks ago
BioSpace, 1 week ago
Manufacturing Chemist, 2 weeks ago
BioSpace, 4 weeks ago
PMLive, 1 month ago
WLTZ 38, 1 month ago
Yahoo! Singapore, 1 month ago
Meetings Net, 1 month ago

BRIEF-Six Japanese drugmakers will team up to discover new cancer, depression treatments - Nikkei

May 25 Nikkei: * Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical,Chugai Pharmaceutical will collaborate with 4 research institutions - Nikkei * The Six Drugmakers will work with research organizations providing ...
 Reuters UK6 days ago Eisai Pharma to introduce new drugs, says MD  Business Line1 month ago

New Data for Eisai's Halaven® (eribulin) and Lenvima® (lenvatinib) in Hard to Treat Cancers will be Presented at Forthcoming American Society of Clinical Oncology (ASCO) Meeting

ASCO invites six abstracts on new Halaven® (eribulin) data in liposarcoma and solid tumours, and new lenvatinib data in thyroid cancers and in renal cell carcinoma Six abstracts that feature new study results in hard to treat cancers ...
 Sys-Con India1 week ago
DNA India

Glenmark bags FDA approval for new generic

Glenmark's drug is the generic version of Eisai's drug Bengaluru: Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for its Rufinamide Tablets USP, 200 mg and 400 mg, ...
 Bio Spectrum Asia1 week ago Glenmark Pharmaceuticals receives ANDA approval for Rufinamide Tablets USP, 200 mg and 400 mg  Equity Bulls6 days ago Glenmark Pharma receives USFDA nod for Rufinamide tablets  MyIris1 week ago Glenmark Gets US Approval For Banzel Generic With 6-Month Exclusivity  Businessworld India1 week ago
Pharmaceutical Technology

Eisai's Lenvima receives FDA approval for new indication

Eisai has received approval from the US Food and Drug Administration (FDA) for a new indication of its anticancer agent, Lenvima (lenvatinib mesylate), as a treatment for advanced renal cell carcinoma. The approval expands the use of Lenvima to ...
 Pharmaceutical Technology2 weeks ago FDA backs Eisai's Lenvima for renal cancer  Pharma Letter2 weeks ago
Money Control

Dr Reddy's ties up with Eisai

Hyderabad-based Dr Reddy's Laboratories (DRL) has entered into a licensing agreement with Eisai by which it will get exclusive development and commercialisation rights (excluding Japan and Asia) for Eisai's investigational anti-cancer agent E7777. The company ...
 The Telegraph2 months ago Dr. Reddy's inks licensing pact with Japan's Eisai  Myiris2 months ago Dr Reddy’s, Japan’s Eisai in licensing pact for anti-cancer agent  Business Line2 months ago Dr. Reddy's acquires E7777s rights from Eisai  India Infoline2 months ago

BRIEF-Eisai says European Commission approves Halaven for treatment of advanced Liposarcoma in Europe

News and Media Division of Thomson Reuters Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, ...
 Reuters UK3 weeks ago European approval for Eisai's Halaven for advanced liposarcoma05-05-2016  Pharma Letter3 weeks ago Eisai's Halaven gains new cancer indication in Europe  pharmaphorum3 weeks ago Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe  Pharmafile3 weeks ago

Dr. Reddy’s in licensing agreement with Eisai

To develop, commercialise the Japanese firm’s investigational anticancer agent E7777
 The Hindu2 months ago Dr Reddy's inks pact with Japan's Eisai for developing anticancer agent  DNA2 months ago

Ureter Cancer Pipeline Repoty H1 2016 - Review of Altor BioScience, Eisai, Exelixis & Merck & Their Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Ureter Cancer - Pipeline Review, H1 2016" report to their offering. Research and Markets has announced the addition of the "Ureter Cancer - Pipeline Review, H1 2016" report to their offering.
 Minyanville1 week ago 2016 Hypersensitivity Therapeutics Market Analysis  Before It's News2 weeks ago Global Malignant Melanoma Drug Market & Clinical Pipeline Insight  Research and Markets3 weeks ago 2016 United States Alzheimer's Disease Drug Industry Review  MyNewsDesk1 day ago
India Infoline

Lupin launches generic Aricept tablets in US market

Lupin's product is a generic version of Eisai Inc's Aricepttablets which is indicated for the treatment of dementia of the Alzheimer's type. The Mumbai-based firm is manufacturing and supplying the product to the US from its Goa facility. It said in a ...
 Economic Times2 months ago Lupin ends higher on launch of Alzheimers drug in the US  India Infoline2 months ago Lupin introduces Generic Aricept Tablets in the US  India Infoline2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
Get updated on latest news & your favorite topics right in your inbox!
More     Less